This is the authors' abstract. We don't add key points for this paper.
Current advancements in antiretroviral therapy (ART) have turned HIV-1 infection into a chronic and manageable disease. However, treatment is only effective until HIV-1 develops resistance against the administered drugs. The most recent antiretroviral drugs have become superior at delaying the evolution of acquired drug resistance. In this review, the viral fitness and its correlation to HIV-1 mutation rates and drug resistance are discussed while emphasizing the concept of lethal mutagenesis as an alternative therapy. The development of resistance to the different classes of approved drugs and the importance of monitoring antiretroviral drug resistance are also summarized briefly.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Iyidogan et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: